Endpoints News
Hengrui China obesity trial dogged by side effects Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M Tue W Th F
7 July, 2026
sponsored by katalyze
Katalyze raises $10.5M as five of the top twenty global pharma companies run its agents in production
Deviation and OOS investigations stall because the answers sit fragmented across Veeva, SAP, historians, and paper. Built with more than a hundred tenured scientists from companies including Sanofi, Pfizer, and Lilly, Katalyze grounds its agents in an Operational Data Layer, so every answer traces to a source, and deploys into existing GxP systems with no change to architecture. Customer teams have cut deviation investigations by 50%, lifted throughput 25%, and helped deliver more than 10 million doses to patients.
See how it works
top stories
1. Novartis, Vertex and Ipsen extend pharma's M&A spree after 45 first-half acquisitions
2. Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials
3. Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing
4.
news briefing
MeiraGTx strikes royalty deal; Fore's 2023 Series D continues
5. Vertex makes $10B deal for commercial endocrinology biotech Crinetics
6. French gene therapy biotech gets €33M to follow Krystal's blueprint
7. CMS proposes 340B cuts
8. FDA approvals outrun staff cuts: 23 novel drugs mark the best first half in three years
more stories
• 
Alex Hoffman
.

As M&A trends emerge, Kyle LaHucik is always ready to provide insightful analysis. Three acquisitions of $10 billion or more have been announced in the last month, and the dealmaking hasn't stopped there. Even before yesterday's Vertex-Crinetics agreement, Leerink analyst David Risinger told Kyle that "a number of the companies that have not executed M&A are being left in the dust." Read the story here.
.
Alex Hoffman
Copy Chief and News Editor, Endpoints News
1
by Kyle LaHucik

Bio­phar­ma's M&A en­gine is revved up and shows no signs of cool­ing off.

Four com­pa­nies have an­nounced ac­qui­si­tions in the first six days of Ju­ly...

Read the full story
2
by Elizabeth Cairns

The GLP-1 pill be­ing de­vel­oped by Hen­grui Phar­ma and Kail­era Ther­a­peu­tics post­ed de­cent re­sults in two late-stage Chi­na-based tri­als — one in obe­si­ty and the...

Read the full story
Kabir Nath, Compass Pathways CEO
3
by Ayisha Sharma

Com­pass Path­ways said Tues­day that pa­tients in the sec­ond of its two piv­otal psilo­cy­bin tri­als main­tained their re­sponse to treat­ment for at least six months...

Read the full story
Endpoints 11 - Reserve Your Spot
The most differentiated science stays out of public view. This September, the Endpoints newsroom reveals the 11 private companies worth watching, live at the State Room in Boston. See the list first, reserve your spot and save with the early bird rate.
News Briefing: Quick hits from the biopharma web
4
by ENDPOINTS

Plus, news about Kalo­hex­is, Te­va and Agios:

👑 MeiraGTx makes roy­al­ty deal with Ober­land Cap­i­tal: The gene ther­a­py mak­er will getan ini­tial $135 mil­lion...

Read the full story
5
by Kyle LaHucik

Ver­tex Phar­ma­ceu­ti­cals is mak­ing the largest ac­qui­si­tion in its his­to­ry, beef­ing up its com­mer­cial port­fo­lio with a $10 bil­lion takeover of Cri­net­ics Phar­ma­ceu­ti­cals.

The Mon­day...